

medincell.

# **Strategic Co-Development & Licensing Agreement with AbbVie**

April 17, 2024

#### IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING

This presentation contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) the ability of its products to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this presentation relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 28, 2022, (the "Universal Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 24 of the Universal Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This presentation is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this presentation does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this presentation may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this presentation are encouraged to inquire about, and required to comply with, these restrictions.

All information in the presentation speaks only as of (1) the date hereof, in the case of information about the Company and (2) the date of such information, in the case of information from persons other than the Company. The Company does not undertake any duty to update or revise the information contained herein, publicly or otherwise. The Company has not independently verified any third-party information and makes no representation as to the accuracy or completeness of any such information.

UZEDY® is trademark of Teva Pharmaceuticals

# 2024: POTENTIAL FOR A SPECTACULAR YEAR

**UZEDY sales ramp up confirmation**

**mdc-TJK (olanzapine LAI): Phase 3 results and PDSS**

**mdc-CWM first Phase 3 results**

✓ **New partners**

# **NEW ERA: ACCELERATION FOLLOWING UZEDY® APPROVAL**

**New strategic alliances**

**Pipeline extension**

**Profitability targeted for FY 2026/27**

# POWERFUL PARTNER

# abbvie

**\$54.3 billion revenue\***

**\$7.8 billion on R&D\*\***

--

**Market cap: \$300 billion\*\*\***

**Top 10 large pharma company\*\*\*\***



**60+**

conditions treated



**175+**

countries where products help people and patients



**62MM+**

people treated by AbbVie's products every year



**50,000+**

employees working in 70+ countries

\* Total net revenues in 2023

\*\* Adjusted R&D investment in 2023 as presented in AbbVie's 2024 Proxy Statement. Adjusted R&D investment reflects 2023 adjusted non-GAAP R&D expense as well as acquired IPR&D and milestones expense and is a non-GAAP measure.

\*\*\* Market cap as of April 8, 2024

\*\*\*\* Based on market cap

Source: [www.abbvie.com](http://www.abbvie.com); Accessed April 8, 2024

# POWERFUL ALLIANCE

medincell.



abbvie

Leveraging Medincell's commercial-stage long-acting injectable technology and development know-how

Capitalizing on AbbVie's regulatory and clinical expertise, manufacturing and commercial capabilities, and global infrastructure to deliver innovative therapeutic solutions to patients globally

# **STRATEGIC CO-DEVELOPMENT AND LICENSING AGREEMENT**

## **Up to 6 Long-Acting Injectable therapies**

- Multiple therapeutic areas and indications
- First program candidate selected; formulation activities underway

**Medincell to conduct formulation and preclinical activities**

**AbbVie to conduct clinical development**

**AbbVie responsible for commercialization globally**

# FINANCIAL METRICS

**\$35 million upfront payment**

up to **\$1.9 billion**  
**in potential commercial and development milestones**  
(up to \$315 million for each program)

**Tiered**  
**mid-single to low-double digit royalties**



# **CASH VISIBILITY TO BRIDGE TO OPERATING PROFITABILITY**

**Cash position as of September 30, 2023: €26.8 million**


**Main cash payments received after the closing**

- €4.2 million from the 2022 Research Tax Credit
- €2.7 million from the Gates Foundation for collaboration on the mdc-WWM program

# IMPACT ON MEDINCELL

- ✓ **Medincell enters new era**
- ✓ **Pipeline extension**
- ✓ **Cash visibility to bridge to operating profitability**
- ✓ **High potential of value creation**

# GROWING R&D PIPELINE



# 2024: POTENTIAL FOR A SPECTACULAR YEAR

**UZEDY<sup>®</sup> sales ramp up confirmation**

**mdc-TJK (olanzapine LAI): Phase 3 results and PDSS**

**mdc-CWM first Phase 3 results**

✓ **New partners**

medincell.

**More to come...**

April 17, 2024